Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer

被引:63
作者
Beckmann, GK
Hoppe, F
Pfreundner, L
Flentje, MP
机构
[1] Univ Wurzburg, Klin & Poliklin Strahlentherapie, Dept Radiat Oncol, D-97080 Wurzburg, Germany
[2] Univ Wurzburg, Dept Otorhinolaryngol, Wurzburg, Germany
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2005年 / 27卷 / 01期
关键词
advanced head and neck cancer; phase I/II trial; concurrent radiochernotheral; weekly cisplatin; concomitant boost radiotherapy;
D O I
10.1002/hed.20111
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background. The purpose of this study was to determine the feasibility and efficacy of hyperfractionated accelerated radiotherapy (HFRCB) combined with simultaneous chemotherapy with weekly cisplatin (CDDP) in locally advanced inoperable head and neck cancer. Methods. From August 1999 to December 2002, 37 patients (median age, 59 years) with Union Internationale Contre le Cancer stage III (n = 2) and stage IV (n = 35) squamous cell cancer of the oropharynx and hypopharynx were treated in a prospective phase I/II trial. Concomitant boost radiotherapy (1.8 Gy, days 1-38 and 1.5 Gy boost, days 22-38, twice daily with at least a 6-hour interval; total dose 69.9 Gy) and simultaneous cisplatin, 40 mg/m(2) weekly, were given. Results. The median treatment duration was 42 days (range, 38-46 days). Toxicity was manageable, with neutropenia grade III/IV and thrombocytopenia grade IV in seven and one patients, and mucositis grade III/IV in 27 and five patients, respectively. Chemotherapy was restricted to four weekly applications in 29 patients mainly because of mucosal toxicity with a median dose intensity of 160 mg/m(2) (0-200) of cisplatin in 5.5 weeks, With a median follow-up of 28 months for living patients, the 2-year overall survival rate was 67%. The median overall and relapse-free survival times were 36 and 31 months, respectively. Conclusion. HFRCB in combination with weekly cisplatin achieves a high rate of locoregional control and survival. Four weekly cycles of 40 mg/m(2) cisplatin seem to be the dose limit for most patients. (C) 2004 Wiley Periodicals, Inc.
引用
收藏
页码:36 / 43
页数:8
相关论文
共 29 条
[1]   Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer [J].
Adelstein, DJ ;
Li, Y ;
Adams, GL ;
Wagner, H ;
Kish, JA ;
Ensley, JF ;
Schuller, DE ;
Forastiere, AA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :92-98
[2]   CONCOMITANT BOOST RADIOTHERAPY SCHEDULES IN THE TREATMENT OF CARCINOMA OF THE OROPHARYNX AND NASOPHARYNX [J].
ANG, KK ;
PETERS, LJ ;
WEBER, RS ;
MAOR, MH ;
MORRISON, WH ;
WENDT, CD ;
BROWN, BW .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 19 (06) :1339-1345
[3]   Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: A randomised phase II EORTC trial [J].
Bartelink, H ;
Van den Bogaert, W ;
Horiot, JC ;
Jager, J ;
van Glabbeke, M .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (05) :667-673
[4]   Radiation techniques for head and neck tumors [J].
Bratengeier, K ;
Pfreundner, L ;
Flentje, M .
RADIOTHERAPY AND ONCOLOGY, 2000, 56 (02) :209-220
[5]   Applications of two-step intensity modulated arc therapy [J].
Bratengeier, K .
STRAHLENTHERAPIE UND ONKOLOGIE, 2001, 177 (08) :394-403
[6]   Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer [J].
Brizel, DM ;
Albers, ME ;
Fisher, SR ;
Scher, RL ;
Richtsmeier, WJ ;
Hars, V ;
George, SL ;
Huang, AT ;
Prosnitz, LR .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (25) :1798-1804
[7]  
BUDACH VG, 2000, INT J RAD ONCOL BI S, V48
[8]   Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma [J].
Calais, G ;
Alfonsi, M ;
Bardet, E ;
Sire, C ;
Germain, T ;
Bergerot, P ;
Rhein, B ;
Tortochaux, J ;
Oudinot, P ;
Bertrand, P .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (24) :2081-2086
[9]   COMBINED TREATMENT OF RADIATION AND CIS-DIAMMINEDICHLOROPLATINUM(II) - A REVIEW OF EXPERIMENTAL AND CLINICAL-DATA [J].
DEWIT, L .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1987, 13 (03) :403-426
[10]   A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer [J].
Dische, S ;
Saunders, M ;
Barrett, A ;
Harvey, A ;
Gibson, D ;
Parmar, M .
RADIOTHERAPY AND ONCOLOGY, 1997, 44 (02) :123-136